Candida auris‒Associated Hospitalizations, United States, 2017-2022

Using a large US hospital database, we describe 192 Candida auris‒associated hospitalizations during 2017-2022, including 38 (20%) C. auris bloodstream infections. Hospitalizations involved extensive concurrent conditions and healthcare use; estimated crude mortality rate was 34%. These findings und...

Full description

Saved in:
Bibliographic Details
Published inEmerging infectious diseases Vol. 29; no. 7; pp. 1485 - 1487
Main Authors Benedict, Kaitlin, Forsberg, Kaitlin, Gold, Jeremy A W, Baggs, James, Lyman, Meghan
Format Journal Article
LanguageEnglish
Published United States Centers for Disease Control and Prevention 01.07.2023
Subjects
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
Associated Hospitalizations, United States, 2017–2022
Candida
Candida auris
Candidiasis, Invasive - drug therapy
Disease control
Disease prevention
epidemiology
fungal infections
fungi
Health surveillance
Hispanic people
Hospitalization
hospitalizations
Hospitals
Humans
Infections
Intensive care
Medical equipment
Medical laboratories
Mortality
Research Letter
United States
United States - epidemiology
United States
New York
Atlanta Georgia
Georgia
United States > US
Candida auris
epidemiology
United States
fungi
hospitalizations
fungal infections
Online AccessGet full text

Cover

More Information
Summary:Using a large US hospital database, we describe 192 Candida auris‒associated hospitalizations during 2017-2022, including 38 (20%) C. auris bloodstream infections. Hospitalizations involved extensive concurrent conditions and healthcare use; estimated crude mortality rate was 34%. These findings underscore the continued need for public health surveillance and C. auris containment efforts.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1080-6040
1080-6059
DOI:10.3201/eid2907.230540